Skip to main content
Clinical Trials/NCT02709629
NCT02709629
Completed
Not Applicable

The Effects of Computerized Cognitive Training on Diabetic Elderly, Who Are at High Risk for Dementia

Sheba Medical Center1 site in 1 country85 target enrollmentAugust 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes
Sponsor
Sheba Medical Center
Enrollment
85
Locations
1
Primary Endpoint
Change from baseline in global cognition as reflected in a composite cognitive score at 9 weeks
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The current study examines the efficiency of a home-based computerized cognitive training (CT) intervention targeting older adults with diabetes.The primary aim of the study is to evaluate the effects of CCT on cognitive and disease management in non-demented older diabetes adults. Investigators will also evaluate the effect of the intervention on a range of secondary outcomes, including mood, caregiver burden, self-efficacy, and for a small sub-sample, on brain activity as reflected in changes in task-related blood-flow on fMRI.

Detailed Description

Evidence suggests a link between diabetes-related processes and increased risk of cognitive decline and dementia in older adults. Optimal disease self-management may be key in the prevention of cognitive decline among older diabetic patients, but this may be compromised due to sub-clinical cognitive impairment. In the current study, 120 community-dwelling, non-demented participants aged 65 and over, with a diagnosis of Type 2 diabetes will be randomly assigned either to an 8-week, home-based individually-tailored CCT program with adaptive difficulty level, and regular performance feedback, or to an 8-week, home-based active control (AC) condition, involving training on a generic CCT program with fixed difficulty level and without performance feedback. Both intervention groups also include a range of theory-informed behavior change techniques (BCTs), including self-efficacy management, self-monitoring and goal-setting in order to enhance treatment fidelity, and to maximize treatment compliance and adherence. In both groups, participants train approx. 30 min. per day, 3 times per-week for 8-weeks. Participants undergo a comprehensive evaluation of all outcomes at baseline, immediately after the intervention, and at a 6-month follow-up, with 1-week booster training completed 3 months from completion of the intervention.

Registry
clinicaltrials.gov
Start Date
August 2015
End Date
December 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Alex Bahar-Fuchs

Dr Alex Bahar-Fuchs

Sheba Medical Center

Eligibility Criteria

Inclusion Criteria

  • Age 65 and over
  • diagnosis of type 2 diabetes
  • Health cover provided by Maccabi Health Services (MHS)
  • Access to a home computer and internet connection
  • Availability of a close relative/informant with regular and frequent contact with the participant (at least 10 hours per week), willing to respond to questionnaires at all time points.
  • Fluency in Hebrew or English
  • Living in the Tel-Aviv metropolitan area and surrounds

Exclusion Criteria

  • An existing diagnosis of dementia
  • Prescription of dementia-related medication.
  • Participation in a previous cognitive intervention study in the preceding year.
  • Significant hearing/vision impairment likely to interfere with assessment and/or training
  • Significant psychiatric/neurological or medical issues that may affect cognitive function.

Outcomes

Primary Outcomes

Change from baseline in global cognition as reflected in a composite cognitive score at 9 weeks

Time Frame: 9 weeks

Change from baseline in diabetes self management as reflected in the diabetes self-management questionnaire

Time Frame: 9 weeks

Secondary Outcomes

  • Change in domain-specific cognitive abilities (memory, non-memory) measured by composite scores from the neuropsychological test battery, at 9 weeks(9 weeks(immediately post-intervention))
  • Change in domain-specific cognitive abilities (memory, non-memory) measured by composite scores from the neuropsychological test battery, at 35 weeks(35 weeks (6 months follow up))
  • Change in meta-memory (subjective ratings of memory performance), as reflect on the Meta-Memory Questionnaire, at 35 weeks(35 weeks (6 months follow up))
  • Change in blood sugar levels on a blood glucose test at 35 weeks(35 weeks)
  • Change from baseline in global cognition as reflected in a composite cognitive score at 35 weeks(35 weeks)
  • Change in meta-memory (subjective ratings of memory performance) as reflect on the Meta-Memory Questionnaire at 9 weeks(9 weeks)
  • Change in self-reported mood-related symptoms on the geriatric depression scale at 9 weeks(9 weeks)
  • Change in informant-reported care-giving burden on the Zarit Burden Interview at 35 weeks(35 weeks (6 months follow up))
  • Change from baseline in diabetes self-management as reflected in scores on the diabetes self-management questionnaire at 35 weeks(35 weeks)
  • Change in self-reported mood-related symptoms on the geriatric depression scale at 35 weeks(35 weeks (6 months follow up))
  • Change in informant-reported care-giving burden on the Zarit Burden Interview at 9 weeks(9 weeks)

Study Sites (1)

Loading locations...

Similar Trials